AHA 2019: DCRI Study Tests Apixaban versus Warfarin in New Patient Population
Apixaban may be a reasonable treatment option for patients with atrial fibrillation who also have renal disease and are receiving hemodialysis, according to late-breaking clinical trial results from RENAL-AF presented Saturday, Nov. 16 at the American Heart Association Scientific Sessions 2019.
DCRI Faculty Recognized on Global “Highly Cited” List
Fifty-four researchers from Duke, including nine from the DCRI, were recognized for their high citation rates.
Data Monitoring Committees Need Complete Data to Protect Patients
Data monitoring committees (DMCs) play a critical role in clinical trials by protecting patients—especially in studies involving high-risk populations or potentially harmful treatments—and in order to fulfill this role successfully, these committees should have access to all data at each interim review, wrote the authors of a recent paper published in the Annals of Internal Medicine.
AHA 2019: Data Highlight Differences in Discrimination of Noninvasive CAD Testing
A new analysis of a DCRI study revealed that younger patients and older patients may need to undergo different types of testing for coronary artery disease in order to more accurately predict risk.
AHA 2019: Type 2 Myocardial Infarction Results in Higher Risk Than Type 1
Patients who experience Type 2 myocardial infarction are at higher risk for additional cardiovascular events and death than patients who experience Type 1 myocardial infarction (MI), according to a new analysis from the DCRI. The analysis, which the DCRI’s Chiara Melloni, MD, presented as an oral abstract Saturday at the American Heart Association Scientific Sessions 2019 in Philadelphia, examined data from three completed DCRI-led trials to shed new light on the differences between patients who experience Type 1 MI and those who experience Type 2 MI.
DCRI Contributes to Important Results Presented at AHA 2019
The DCRI served as the statistical and data coordinating center for ISCHEMIA, a late-breaking clinical trial that indicated invasive heart procedures may not reduce the chance of experiencing a maj
DCRI to Partner With Amgen on Large-Scale Registry
By enrolling 8,500 high-risk patients with a recent atherosclerotic cardiovascular disease event, cvMOBIUS will be the first large-scale registry to evaluate real-world lipid management and the effectiveness of PCSK9 inhibitors.
Innovating Adjudication
As the DCRI’s Clinical Events Classification (CEC) group grows, its leaders are seeking innova
DCRI Researchers Weigh In On Wearables in Heart Failure Care
Researchers from the DCRI are optimistic about the opportunities that wearable devices present in caring for patients with heart failure; however, they also recognize that challenges must be overcome to successfully interpret and act upon patient data collected from wearables.
Tool to Assess Cardiovascular Risk May be Inaccurate in Older Adults
A DCRI-led study is the first to test the performance of the Pooled Cohort Risk Equations, a commonly used tool for assessing cardiovascular risk, in older adults.